Last updated on October 2018

Study to Evaluate the Safety of Repatha in Pregnancy

Brief description of study

To evaluate outcomes of pregnancy in females diagnosed with familial hypercholesterolaemia (FH), exposed to Repatha during pregnancy. This includes follow-up of their infants to the age of 12 months

Detailed Study Description

Women diagnosed with familial hypercholesterolaemia (FH), treated at centres in Europe, South Africa and Australia, with pregnancy confirmed during the study observation period and who provide informed consent to participate in the study.

Exposed subjects are women who received Repatha during pregnancy and/or breastfeeding; unexposed subjects are women who have not received Repatha during pregnancy and/or breast-feeding. In infants, exposure may occur in utero and/or via breast milk, within 15 weeks following the date of Repatha dosing in the mother

Clinical Study Identifier: NCT02906124

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Liberec, Czechia
  Connect »